| Names | |
|---|---|
| Preferred IUPAC name | 2-aminobutanedioic acid |
| Other names | Aspartic Acid D-Aspartate D-Aspartic Acid D-AA D-2-Aminosuccinic Acid |
| Pronunciation | /diːˈɛl əˈspɑːrtɪk ˈæsɪd/ |
| Identifiers | |
| CAS Number | 1783-96-6 |
| Beilstein Reference | 1720469 |
| ChEBI | CHEBI:29961 |
| ChEMBL | CHEMBL1121 |
| ChemSpider | 575 |
| DrugBank | DB00132 |
| ECHA InfoCard | 13bb9dab-60e4-41c3-89b5-6e5d52aca30f |
| EC Number | 205-735-8 |
| Gmelin Reference | 16202 |
| KEGG | C01035 |
| MeSH | D000223 |
| PubChem CID | 6322 |
| RTECS number | AS4375000 |
| UNII | F8VON79AGN |
| UN number | UN9077 |
| CompTox Dashboard (EPA) | DTXSID5027275 |
| Properties | |
| Chemical formula | C4H7NO4 |
| Molar mass | 133.10 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.261 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | –3.89 |
| Vapor pressure | Negligible. |
| Acidity (pKa) | 2.10, 3.90 |
| Basicity (pKb) | 3.89 |
| Magnetic susceptibility (χ) | -5.4×10⁻⁶ |
| Refractive index (nD) | 1.630 |
| Dipole moment | 6.49 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 138.9 J·K⁻¹·mol⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1176.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | −1514 kJ mol⁻¹ |
| Pharmacology | |
| ATC code | A16AA26 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS07: Exclamation mark |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: Not a hazardous substance or mixture according to the Globally Harmonized System (GHS). |
| Precautionary statements | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. |
| NFPA 704 (fire diamond) | Health: 1, Flammability: 1, Instability: 0, Special: |
| Flash point | > 210.3 °C |
| Autoignition temperature | 400 °C |
| Lethal dose or concentration | LD50 (oral, rat): 4,520 mg/kg |
| LD50 (median dose) | LD50 (median dose) of DL‑Aspartic Acid: 16,000 mg/kg (rat, oral) |
| NIOSH | Not established |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for DL‑Aspartic Acid: Not established |
| REL (Recommended) | 3 g daily |
| Related compounds | |
| Related compounds | L-Aspartic acid N-Acetylaspartic acid Aspartate Glutamic acid Succinic acid |
| Property | Description |
|---|---|
| Product Name | DL‑Aspartic Acid |
| IUPAC Name | 2-Aminobutanedioic acid |
| Chemical Formula | C4H7NO4 |
| Synonyms & Trade Names | DL-Aspartate; Racemic Aspartic Acid |
| HS Code & Customs Classification | 2922.49 for non-proteinogenic amino acids and derivatives; exact code may vary by jurisdiction and intended application |
Production of DL‑Aspartic Acid in a manufacturing facility involves the racemization of L‑aspartic acid or synthesis from petrochemical routes such as the ammonolysis of maleic anhydride. Raw material selection considers ammonia purity, anhydride source, and batch traceability. The racemization degree and process route influence both the yield and the impurity profile; segregating mother liquor management and side product handling becomes a practical concern. Critical control points include reaction pH, temperature profile, and anti-solvent dosing for crystallization. In-process monitoring tracks conversion, potential racemization inefficiencies, and byproduct accumulation.
Grade is driven by the end-use: technical grade for industrial bulk applications, refined grades for food, feed, or specialty uses. Higher grade requirements often intensify purification—this can involve additional recrystallization, activated carbon treatment, or tailored filtration steps. The chosen process route directly impacts what residual impurities require attention, as certain synthesis routes produce specific byproducts. Customer requirements may dictate the allowable chloride, sulfate, or specific residual organic contaminants.
Moisture uptake and caking are frequently observed in humid environments. Particle size affects flow in downstream processing and is managed post-crystallization through controlled drying and sieving operations. Bulk density and free-flowing characteristics depend on the production batch and finishing operation. Storage is set up for segregation between DL-, D-, and L- forms due to cross-contamination risks and regulatory obligations.
Batch-to-batch consistency depends on both raw material variances and process stability. Internal quality criteria reflect not only analytical results for primary constituents but also impurity profiling tailored to both process history and customer approval dossiers. Release standards integrate in-process results and final off-line analytics, with specifications customized to the product grade and contractual end use.
In typical industrial production, DL‑Aspartic Acid is isolated as a white to off-white crystalline solid. Powdered forms exhibit free-flowing properties, with visual assessment remaining the first screening method for lot consistency. Odor typically remains negligible or “neutral” if the purification stage controls side-reaction byproducts; noticeable odor often signals process deviation or contamination during drying.
The melting point depends on grade and water content, generally aligning with the racemic mixture’s characteristics. Boiling point and flash point measurement are rarely process-critical in bulk manufacturing, as thermal decomposition precedes boiling under atmospheric pressure. Density varies slightly with compaction and moisture uptake, impacting bin transfer and loss-in-weight feeder calibration.
The aspartic backbone handles ambient industrial storage if protected from excessive humidity. Destabilization risks increase in the presence of oxidative agents or elevated heat. Hygroscopicity is minimal under controlled storage but increases with prolonged air exposure and sub-standard packaging.
DL‑Aspartic Acid exhibits moderate solubility in water, strongly influenced by solution pH and temperature. Solution clarity and dissolution rates often mark the effectiveness of the final crystallization and washing procedure; fines, agglomerates, or discoloration require examination of filtration and drying steps. Bulk solution preparation must include agitation protocols, staged temperature ramps, and pH buffer if performance is application-driven (biochemical, food, or pharma intermediate).
DL‑Aspartic Acid grades address variances in purity, particle size, and application requirements. Core grades include technical, food, and pharmaceutical intermediate. Typical values depend on grade and application; detailed specifications can be defined according to project or customer criteria.
| Grade | Purity (w/w%) | Moisture (%) | Loss on Drying (%) | Heavy Metals (ppm) | Particle Size |
|---|---|---|---|---|---|
| Technical | Grade-dependent | Grade-dependent | Grade-dependent | Grade-dependent | As specified by user |
| Food | According to food standards | Application-sensitive | Defined by food law | Supplier complies with local limits | End-use defined |
| Pharma Intermediate | Higher purity | Lower residual water | Controlled | Stricter limits | Defined by formulation |
Impurity content is shaped by both synthesis route and purification efficiency. Key monitored impurities originate from incomplete conversion (precursor residues), racemization byproducts, trace heavy metals from catalysts or raw materials, and side-products from over-oxidation or dehydration. Release limits follow the most stringent between internal spec, downstream validation, and local regulation.
Release testing includes HPLC, titration, and residue-on-ignition by established pharmacopoeial or food additive methods, if specified. Particle size and bulk density sampling align with downstream process requirements. Final release is subject to internal QC criteria and customer requirements. Full traceability relies on batch-based analytical records.
Suppliers select fumaric acid, ammonia, and catalytic hydrogenation sources according to cost, local regulations, and impurity background. Bulk-sourced, audit-backed raw material contracts reduce batch-to-batch variance. Feedstock quality has downstream effects on color, yield, and impurity spectrum.
Producers favor routes allowing robust racemic mixture generation — e.g., fumaric acid ammonolysis or alkali-catalyzed addition — balancing yield, cost, and byproduct minimization. Route selection considers waste stream handling and energy usage profiles as much as conversion efficiency.
Reactors monitor pH, temperature, and reagent feed rates through continuous or batch-wise QC. Incomplete reactions, local overheating, and oxygen ingress raise impurity risks. Purification relies on staged crystallization, followed by filtration and washing to exclude both soluble and insoluble byproducts. Dryer control must prevent localized overheating, caking, or caramelization, which create off-spec product.
Batch consistency is tracked by in-process analytics, finished product inspection, and trending of critical impurity markers. Variations in color, odor, or moisture prompt root-cause investigation, as these often link to upstream deviation. Product passes release only after meeting all criteria for grade, impurity content, and application-specific requirements.
DL‑Aspartic Acid acts as a substrate for amidation, esterification, salt formation, and peptide synthesis. Reaction preference aligns with the desired end-use, labile hydrogen positions, and activation energy accessed by customer processes.
Many modifications require acid or base catalysis, moderate heating, or water-privative solvents. Selection depends on yield, purity, and downstream risk assessment. Required catalyst and temperature profiles are specified by the application process.
Key derivatives include aspartate salts, esters, and peptide building blocks. Processing decisions in the first synthetic step influence not only yield but also compatibility with enzymatic conversions or subsequent coupling stages.
DL‑Aspartic Acid should be kept in tightly sealed containers, protected from excess humidity and temperature swings. Light exposure rarely degrades the bulk solid but may signal risks of container failure in clear or thin-wall packaging. Inert gas protection is considered for grades subject to moisture or oxidation risk in long-term storage.
Packing materials must show chemical compatibility without leaching, puncture, or static charge hazards. Bulk lots employ heavy-gauge polyethylene liners, fiber drums, or coated metal bins, barring reactive surfaces. Use of standardized secondary containment limits cross-contamination.
Shelf life depends on grade, packaging, and storage. Appearance of clumping, discoloration, or off-odor signals hygroscopic uptake, impurity evolution, or post-packaging contamination, all grounds for rejection prior to use.
Hazard classification aligns with global standards based on physical and toxicological test data; food and pharmaceutical intermediates generally fall in low-to-moderate concern categories absent specific sensitization or chronic exposure evidence.
Manufacturing teams note dust generation and possible mild irritation during handling; operators employ dust masks, gloves, and, where fine powder is processed, dust extraction or local ventilation. Zero-tolerance policies apply to cross-contamination in food or pharma production.
Acute ingestion toxicity rests at low levels for this amino acid, but high airborne concentrations can cause mucous membrane discomfort. Chronic exposure thresholds and maximum allowable workplace concentrations remain dependent on local regulation. All plant personnel undergo regular safety training, with special attention to allergenic and cross-contact controls for food and pharma grades.
Production output for DL‑Aspartic Acid depends heavily on demand from key regions, raw material supply consistency, and the level of process integration at each manufacturing site. Multi-ton capacity can often be allocated for pharmaceutical, food, and technical grades, but actual available output fluctuates according to internal scheduling, market draw, and feedstock access. Commercial contracts frequently require rolling forecasts to secure allocation, especially in peak seasons or for specialized grades.
Lead time varies by production line loading, grade, and whether product is drawn from inventory or scheduled for custom batch production. For standard industrial grades, shipment from stock is sometimes possible within a short period. Custom synthesis, high-purity grades, or customer-specified certifications extend lead times due to added purification, analytical verification, and documentation steps. MOQ reflects efficiency targets in batch size, packaging configuration, and logistics consolidations—technical grade MOQs often being larger than those for research or high-purity lots due to downstream processing costs and changeover requirements.
Packaging selection is driven by regulatory, logistical, and end-use constraints. Fiber drums, HDPE drums, and multi-layered bags are typical for bulk shipments, offering moisture and contaminant protection. Food, pharmaceutical, or electronic grades require tamper-evident seals, full tracking, and, in certain cases, inert atmosphere packing to limit degradation or cross-contamination risk. Container size and labeling meet both domestic transport criteria and destination import requirements.
Shipping terms follow Incoterms with shipments delivered EXW, FOB, or CIF depending on customer negotiation and risk allocation. Temperature-controlled or DG-rated logistics may impose additional lead or cost for grades with special storage requirements. Payment terms for repeat industrial buyers balance between L/C, net 30-60 credit, and partial prepayment, strongly influenced by customer credit profile and transaction history.
DL‑Aspartic Acid production ties raw material expenses to costs of fermentation feedstock, precursors such as ammonia or oxaloacetate derivatives, utilities, and purification reagents. Shifts in the price of sugars or corn (for fermentation), energy volatility, and cost of labor push floor price up or down. Impurity profile and recirculation of byproducts play a pronounced role in technical versus pharma grades—a tighter impurity window or higher optical purity requires more complex processes, raising unit costs significantly.
Price differences stem from product grade (technical, food, pharma), purity level (total and optical), and region-specific certification (USP/EP/JP/FCC compliance or Kosher/Halal status). Pharmaceutical and food grades command a premium due to validation, documentation, and batch traceability. Packaging in small, contamination-resistant containers also elevates costs for electronic and food applications. Certification status and third-party audits further influence released pricing.
Price swings often trace to agricultural commodity cycles, regional weather disruptions (impacting fermentable sugar sources), changes in supply or tariffs for critical reagents, and fluctuations in energy cost. Environmental compliance costs, labor policies, and regional regulatory changes also influence the total landed cost structure.
Global DL‑Aspartic Acid demand tracks closely with amino acid market trends in Asia-Pacific, Europe, and North America, with growth rates modulated by dietary supplement, pharmaceutical, and technical material demand. Asia remains the leading supply base for commodity and food grades, while US/EU often lead in custom, high-value, lower-volume grades. Trade flow interruptions or regulatory changes in China, India, or the US have immediate consequences for global inventory and availability.
China leads bulk production, with efficient integration between fermentation and chemical synthesis lines. India shows growing self-sufficiency, but imports high-purity feedstocks for export-oriented production. Japan focuses on niche high-purity markets and electronic material supply. US and EU remain demand centers for high-certification product, influencing specification development and compliance costs worldwide.
Forward pricing models anticipate continued cost volatility based on Asia-based raw material cost trends, upstream fermentation output, and tightening environmental regulations. Commodity prices hold risk for upward adjustment if agricultural input or energy markets remain unstable. High-purity and certified grades see further premium growth due to rising audit and compliance expenses. Automation and efficiency improvements provide downward pressure, but net trajectory remains upward-biased for all but the most commoditized grades.
Price forecasts rely on spot market transaction records, long-term customer contract averages, energy and raw material futures indices, and internal operational metrics. Market intelligence combines trade data, government customs figures, and direct customer feedback from periodic commercial reviews. Pricing for specialty grades references industry associations and leading market analytics where available.
Major suppliers have announced expanded production lines to buffer against supply chain shocks, raise pharma-grade output, and close loop on solvent recovery. Regional regulatory shifts, such as stricter discharge standards in China and more rigorous FDA/API traceability in the US, alter cost and lead time for affected grades. COVID-19 legacy factors continue to cause logistics volatility in certain regions.
Recent updates in global food additive and pharmaceutical ingredient frameworks raise the threshold for batch release analytics, documentation requirements, and product traceability. Increased enforcement of environmental sustainability and product safety impacts not only production cost but detail required in Certificates of Analysis and batch history transparency.
Manufacturers have implemented advanced real-time process monitoring, backward integration into key raw materials, and global redundancy for high-value-grade output. Internal risk management protocols focus on raw material sourcing diversification, energy efficiency projects, and digitalization of traceability documentation to meet audit standards. For export markets, documentation support and regulatory intelligence teams have expanded to preempt compliance disruption at customs or in downstream applications.
DL-Aspartic Acid produced in our facility finds its main downstream sectors in pharmaceutical synthesis, food and beverage manufacture, biochemical research, and certain technical fields such as plating additives and biodegradable polymers.
Pharmaceutical manufacturers look for material clean enough for use in APIs, intermediates, or excipient matrix systems. Food sector demands focus on nutritional and additive roles, with regulatory oversight shaping limits around purity and contaminants. Researchers and technical processors such as electroplating or polymer synthesis may define purity or reactivity windows differently, driven more by functional outcome.
| Industry | Typical Grade | Processing Focus | Common Quality Concerns |
|---|---|---|---|
| Pharmaceutical | Pharma/USP/EP/JP grade | Purity, trace metals, residual solvents | Compliance with pharmacopeia, microbial load |
| Food & Beverage | Food grade | Microbial status, allergens, heavy metals | Traceability, food safety standards |
| Analytical/Research | Reagent grade | Known impurity profile, batch consistency | Interfering substances, lot-to-lot reproducibility |
| Industrial/Technical | Technical grade | Processing aids, non-pharma requirements | Bulk characteristics, processability |
Pharma and Food: The pathway from raw input to purified DL-Aspartic Acid must control for both process residues and environmental contaminants. In-process analytical checks watch for heavy metals, residual solvents (if organic synthesis routes are used), and bioburden. For food application, allergens and GMO status also prompt scrutiny.
Research or Technical: Users often demand detailed impurity mapping or certificates of analysis that describe trace contaminants. These sectors sometimes accept a broader spec for process optimization but need batch uniformity.
Key metrics depend on product grade, defined jointly by internal QC specs and downstream customer test methods. Each batch release ties to an audit trail: purity, moisture, trace element content, and if required, specific optical isomer composition.
Outline the end use as precisely as possible. API synthesis, nutritional additive, or plating chemical each imply a different set of technical and regulatory expectations. Precise application definition drives everything from grade selection to release documentation.
Pharmaceutical or nutraceutical uses fall under regional and international regulations. Food applications refer to standards such as FCC, GB, or EU food codes. Downstream validation and audits commonly require documented compliance and sometimes site inspections.
Each customer sets purity thresholds in line with their supply chain risk and technical tolerance. Pharma grades go through multi-stage purification and have the narrowest spec window for contaminants. Food grade prioritizes known food risks but may set less stringent thresholds for unrelated process residues. Technical grades accept wider impurity margins if performance is not compromised.
Large-scale industrial or feed applications tend to favor price-per-unit and logistics reliability, accepting technical grade if the downstream process tolerates it. High-purity pharmaceutical runs or clinical R&D lots justify higher cost for rigorous batch tracking and quality documentation.
A practical step is small-scale trialing of representative production sample under actual processing conditions. Customers can audit our batch record, impurity profile, and certificate of analysis against their most critical acceptance criteria before moving bulk volumes.
Feedstock origin determines trace impurity loading from the outset. For regulatory-sensitive applications, only pre-qualified suppliers of starting materials enter our procurement system, with full traceability documentation.
The chosen synthetic pathway (fermentation, chemical synthesis, or enzymatic resolution) impacts impurity profile and downstream refining steps. Route selection balances process efficiency, environmental release, and regulatory acceptability of intermediates.
Multiple stages generate checkpoints: in-process assays verify pH, conductance, and removal of side products. Batch records capture process deviations and corrective actions, helping ensure documented consistency batch-to-batch.
Each manufacturing step defines both type and concentration of unwanted byproducts—unreacted substrates, byproduct acids, metals. Purification design involves crystallization, filtration, and when necessary, chromatography, adjusting to the required grade. The tighter the application spec, the more robust the purification.
Specifications always reflect the final intended grade. Pharma and food applications have tighter verification—microbiological, heavy metals, and organic residues tested under validated methods. Technical grade may focus on bulk chemical properties and processability over impurity mapping.
All release decisions result from both analytical data and documented traceability, with the customer’s regulatory or technical requirements guiding the final criteria on every batch.
Our facility has passed recognized quality management audits focused on chemical synthesis and downstream amino acid processing. Auditors examine documented production controls, traceability from raw material intake to finished batch, and ongoing risk-assessment protocols. Accreditation scope, scope of annual review, and surveillance frequency are shaped directly by the grade of DL‑Aspartic Acid under production and target customer sector.
Certifications for DL‑Aspartic Acid depend on application grade and target market. End-use segments (including food, pharmaceutical, and industrial applications) shape the spectrum of required certifications. Food- and pharma-grade materials require closer documentation ties: process route dossiers, impurity profiling, and synthesis-batch supporting data are produced batch-wise. Industrial grades follow separate internal conformity standards and release criteria, calibrated to the needs of downstream operations such as polymer synthesis or specialty formulation. Whenever new regional or customer-specific directives emerge, our quality team reviews documentation flow and initiates gap closure.
Batch-specific quality reports include raw data from in-process monitoring, analytical release values, and trace records for upstream batch materials. Depending on the final application, we support documentation packages with CoA, COA deviation justification (if a value falls outside the typical range but meets contractual specification), impurity statement, residual solvent status, and—where mandated—statutory declarations regarding the absence of contaminants or substances of very high concern. These document packages differ based on market destination and regulatory definition for the supplied grade.
DL‑Aspartic Acid output depends on raw material availability and batch campaign scheduling. For standard industrial grades, line allocation allows continuous output with safety buffer inventory. Food and pharma segment contracts structure campaign durations differently, with tighter lot separation and test frequency determined jointly by contract and regulation. Supply plans balance customer order windows, buffer inventory minimums, and plant maintenance. Long-term purchase agreements offer customers stability, with flexibility for volume modulation over the contract period.
Production line reservation and feedstock forward-contracting drive supply reliability. For customers with rolling forecasts or multi-quarter volume visibility, we align synthesis schedules to reduce lead times and batch-to-batch variability. The reliability profile reflects route-specific bottlenecks, such as chiral precursor availability or utility outage risk. Where customer usage cycles show seasonality, stock build strategies are jointly defined to prevent disruption. Logistical contingencies account for port congestion or regulatory inspection delays, with allocations managed by production planning and logistics control teams.
Sample requests initiate with application details provided by the customer: target use segment, batch size, grade requirements, and analytical criteria. Our technical support and quality assurance check internal batch records to match the closest lot or synthesize a new mini-batch if atypical specifications are needed. Shipping conforms to classification and packaging based on grade and regulatory group. Customers receive technical data sets to accompany each sample batch, so that early-stage evaluation is representative of contract-scale performance.
We recognize procurement cycles and customer supply chain integration requirements differ by industry and end-market. We support blanket order systems, just-in-time call-off models, and volume-based pricing contracts. Change orders and rescheduling are accommodated through real-time demand planning and production slot adjustment, subject to feedstock and regulatory constraints. Direct factory-to-customer logistics, third-party warehousing, and consignment stock arrangements are implemented according to customer needs, with cross-department review for risk assessment and fulfillment assurance.
Industrial research teams are targeting the improvement of yield and stereoselectivity in biochemical and chemical routes for DL-Aspartic Acid. Existing production relies on various routes, including chemical synthesis and enzymatic fermentation, each with distinct impurity profiles. Development efforts prioritize feedstock efficiency, reduction of raw material input cost, and minimizing process-derived byproducts. R&D work in scale-up settings often revolves around reusability of catalysts, continuous process integration, and automated in-process analytics to enhance reproducibility.
There is growing attention toward functional applications of DL-Aspartic Acid as a building block for biodegradable polymers, specialty resins, and chelators used in industrial water treatment. Pharmaceutical and nutraceutical intermediates have triggered further demand for grades with defined impurity fingerprints and consistent particle morphology. Application sensitivity varies: technical-grade material can tolerate broader impurity windows, while pharma excipient or precursor grades demand batch-by-batch release against more stringent monographs and customer-defined specifications.
Consistent chiral purity, heavy metal residue control, and process water reduction remain persistent challenges. For enzymatic processes, enzyme stability and substrate conversion ratio dictate operational cost. Manufacturers are addressing these through upstream purification, selection of food-grade or pharmaceutical-grade starting materials where required, and closed-loop water recycling. Direct process intensification methods—such as coupling purification with crystallization—have led to noticeable reduction in contaminant carryover and variability in product appearance.
End-use sectors including polymer synthesis, animal nutrition, and pharmaceuticals determine the demand for both DL-Aspartic Acid and its downstream derivatives. While technical-grade consumption may correlate with commodity resin or chelator trends, higher-purity applications in APIs and medical feedstocks reflect regulatory cycles and new registration of active ingredients. Manufacturers relying on flexible plant configurations stand positioned to adapt output volume and impurity profile in response to fast-shifting customer requirements and region-specific compliance frameworks.
Shifting from batch to semi-continuous or fully continuous systems remains a major evolution point. Implementation of real-time monitoring (PAT—Process Analytical Technology) provides tighter release control and improves conformity to agreed quality targets. On-site water recycling, solvent recovery, and digital tracking of production lots have become a baseline in new facility investments. Engineering teams prioritize modular plant design to rapidly switch between grades and accommodate order-driven batch sizes.
Efforts are underway to reduce the reliance on petrochemical-based feedstocks by switching to biobased or renewable raw material streams wherever technically feasible. Waste stream valorization includes recovery of byproducts for secondary use or energy generation. Manufacturers are investigating the use of water-based processing and solvent minimization to align with internal sustainability goals and anticipated regulatory tightening in multiple regions.
Support begins with detailed product grade matching, including evaluation of impurity profiles, residual catalyst levels, and compatibility with target process flows. Technical staff work directly with customer formulation teams to assess how variations in raw material origin or intermediate handling may influence downstream processes or regulatory acceptance. Guidance extends to documentation support for audit and traceability requirements, particularly for regulated use-cases.
Optimization efforts focus on identifying the grade and particle profile best suited to individual customer reactor configurations, blending processes, or product performance constraints. Feedback loops are established for recurring supply to monitor process shifts at the customer site, enabling on-the-fly adjustment of physical parameters or impurity thresholds. For end-use sectors with demanding performance or safety requirements, technical teams will review in-field data and coordinate closely on any root-cause analysis where product characteristics impact client-side yield or quality.
Manufacturers maintain dedicated response lines for customer process deviations linked to each DL-Aspartic Acid batch supplied. Batch documentation, including COA and analytical archives, is retained and made available for agreed retention periods. Quality assurance includes periodic plant audits and customer-driven quality review meetings. For supply under long-term agreements, change notification protocols govern any modification to process route, control parameters, or critical raw material source.
We operate our DL-Aspartic Acid production at scale, using controlled synthesis routes and equipment tailored for bulk industrial supply. Every batch originates from our own facilities, managed by staff who understand the importance of traceability and real-world process controls. Our teams oversee material inputs, maintain strict process parameters, and verify batch consistency against internal reference standards.
Industrial buyers turn to DL-Aspartic Acid for its performance in fields such as pharmaceuticals, food ingredients, agrochemicals, and polymer manufacturing. This compound supports peptide synthesis, serves as a chelating agent, and acts as an intermediate for specialty chemicals. Technical staff at contract manufacturers regularly use DL-Aspartic Acid for custom formulations, protein hydrolysis, and biotechnological processes. Our longstanding business relationships in these markets reflect years of direct supply and feedback cycles with end-users.
Process control and raw material selection anchor our approach to quality. Our on-site chemists run analytical checks at every stage, from pre-treatment to drying and final packing. Lot-to-lot analysis includes chromatography, purity assays, and contaminant profiling, all performed with instrumentation maintained under calibrated schedules. If a client requests additional data points, our lab teams often run supplementary tests to address regulatory or formulation particulars. Records stay linked by production code for straightforward audit trails, enforcing confidence in repeat orders.
We package DL-Aspartic Acid in standard industrial drums, lined or unlined as dictated by customer process compatibility, as well as jumbo bags for high-volume requirements. Packaging integrity gets verified for moisture protection and tamper resistance. Our loading staff coordinates closely with logistics partners for inland and port delivery. Packaging lines at our site can adjust for custom order volumes or special material handling instructions, avoiding bottlenecks and warehouse delays.
Technical inquiries come directly to our in-house chemists and process engineers. If downstream production specialists require solubility data, reaction profiles, or compatibility notes for co-processing, these are addressed by personnel familiar with both the product and how it's manufactured. Process improvement consultations, troubleshooting after installation, and ongoing feedback requests are managed by direct employees—not third parties without process insight. This enables buyers in pharmaceutical, food, and materials sectors to solve sourcing and technical bottlenecks in real time.
For manufacturers, procurement leaders, and distributors, a stable upstream partner secures both price predictability and reliable lead times. Our direct role in synthesis, packaging, and QA control cuts downstream risk and reduces the chance of disruption in supply contracts. Buyers looking for predictable quality batches, full documentation, and technical access benefit from a clear link to the actual production operation. Our record of multi-year contracts, GMP-compliant batches for regulated industries, and scalable supply for emerging markets demonstrates ongoing alignment with buyer priorities.
DL-Aspartic Acid has attracted a lot of attention across various sectors that rely on amino acid products. As the direct manufacturer, we receive questions about molecular weight and chemical formula almost every week from clients seeking precision in their formulation processes. Knowing these details is not just a theoretical matter. It’s fundamental for accurate dosing, process control, and proper handling.
Our production process for DL-Aspartic Acid targets high purity standards and crystal clarity around the molecule’s structure. The chemical formula for DL-Aspartic Acid is C4H7NO4. This formula applies whether the interest lies in food, pharmaceutical, or industrial applications. The “DL” designation means the product is a racemic mixture: it contains equal proportions of both the D- (dextrorotatory) and L- (levorotatory) enantiomers. We constantly monitor this balance. Chirality affects the performance in downstream formulations, and our technical team puts significant effort into confirming that our batches provide the specified racemate ratio.
The precise molecular weight for DL-Aspartic Acid is 133.10 g/mol. Our facility’s analytical department verifies this figure using mass spectrometry and NMR testing methods, as part of our routine quality control cycle. Inconsistent molecular weights might indicate impurities or incorrect isomer ratios. Our adherence to this figure assures our clients that they are obtaining reliable, consistent product in each lot delivered. In larger-scale production, even minor deviations in molecular weight can cause measurable discrepancies in process yield or product stability. Customers in the pharmaceutical and biotech industries count on this reliability for regulatory submissions and process validation.
Incorrect data disrupts efficiency. Many customers formulate advanced products—chelated mineral blends, culture media, sports nutrition, or biochemical reagents—where every milligram factors into cost and performance. By providing trusted, verifiable molecular data, we help prevent wastage and error in formulation, mixing, and labeling. Over time, that accuracy plays a direct role in manufacturing economics and predictable production scale-up.
To maintain consistent molecular weight and molecular structure, our plant employs robust feedstock sourcing, multi-step purification, and stringent parameter controls. Automated reactors track temperature, pH, and reaction endpoints to lock in the aspartic acid synthesis. Each lot receives full-identity confirmation by our quality control chemists before packing. If any shift in physical or chemical profile is observed, the lot is held back for further review, protecting client operations from supply chain doubt.
Every batch ships with a certificate of analysis confirming both molecular weight and formula, along with enantiomeric purity data when required. For research or regulated manufacturing, our technical team provides extended documentation and testing details. Maintaining factual, clearly stated molecular records doesn’t just check a box—it builds trust in every delivery from our facility to your door.
Supplying DL-Aspartic Acid at industrial scale demands reliable production lines, robust logistics, and direct access to the source. As the original manufacturer, we ensure direct bulk availability from our chemical plant without intermediaries. Our entire process—from raw material sourcing, synthesis, quality checks, to final packaging—remains under our control. This direct chain keeps supply dependable and eliminates guesswork about the product’s history or quality traceability.
We manufacture DL-Aspartic Acid year-round on production lines designed for uninterrupted output. Continuous operation makes large batches possible even during peak ordering seasons. Our plants use streamlined batch-processing reactors and filtration equipment sized for industrial volume, so chemical buyers and formulators in food, pharma, or technical fields will encounter no interruption in their downstream processes.
Before shipping, every lot receives analytical documentation from our in-house laboratory. We run HPLC purity profiles and moisture content checks on each batch. Our consistent crystal morphology supports efficient handling at the customer’s facility, whether the acid is headed for blending, custom compounding, or further chemical synthesis.
We define a clear minimum order for DL-Aspartic Acid: one full pallet load. Depending on the standard packaging—in fiber drums, lined woven bags, or bulk sacks—each pallet contains several hundred kilograms. Large-volume orders, measured in metric tons, can be filled as regularly scheduled shipments, allowing for just-in-time delivery.
Uninterrupted supply matters most for partners planning longer-term production runs. For annual contracts or repeated bulk draws, we reserve custom production slots and dedicated warehouse space. Batch traceability, documentation, and logistics integration with the recipient’s system are likewise directly managed between our technical team and the end-user’s procurement or quality control department.
Purchasers that rely on direct manufacturer supply tap into stable pricing, batch-to-batch consistency, and a technical resource who understands the nuances of DL-Aspartic Acid chemistry. The route from synthesis to packing follows protocols refined through regulatory inspections and customer audits. Our operation follows current manufacturing best practices to keep product contaminants and cross-contact risk at bay.
Bulk availability also enables customized labeling, packaging, and even supply chain validation. Whether a client specifies tamper-evident closures, specialized pallets, or additional purity documentation, our in-house team can fulfill these needs to support downstream regulatory filings or internal process specifications.
Having direct control over inventory and shipping cycles means urgent project launches and production spikes can be met without sourcing delays. At the same time, our transparent approach to minimum order quantities cuts down on logistics confusion and unnecessary surcharges. We focus on building pragmatic, predictable relationships with both established and scaling industry partners.
Inquiries on customization, long-term arrangements, and exact order fulfillment logistics can always be handled directly by our technical and commercial management teams. DL-Aspartic Acid never passes through hands outside our quality system, from the reactor to the customer’s facility dock. By keeping the process tight, we uphold reliability across each supply phase.
Producing DL‑Aspartic Acid in large volumes means every shipment faces thorough regulatory scrutiny. Most customers expect prompt, hassle-free delivery, so we navigate compliance seriously. As a non-hazardous, non-toxic amino acid derivative, DL‑Aspartic Acid generally travels without restrictions typical to dangerous goods. Our logistics team confirms each batch aligns with domestic and global transportation codes, especially those applying to chemicals.
International shipping corridors, including the US, EU, and much of Asia, do not list DL‑Aspartic Acid as a controlled or regulated chemical, provided purity specifications and intended uses match food, feed, or industrial applications. We reference current Harmonized System (HS) Codes, classify DL‑Aspartic Acid typically under amino acids not elsewhere specified, and document customs declarations accordingly. This avoids confusion at customs and smooths clearance. For reference, DL‑Aspartic Acid does not appear in Annex I of the European REACH regulation, and shipments to North America do not require registration under TSCA or similar chemical inventories, based on current regulatory status and use cases.
Every shipment receives a detailed Certificate of Analysis and Safety Data Sheet, created by our technical department, to address regulatory or inspection inquiries during transit. Clear, traceable batch numbers and well-prepared customs invoices further prevent delays at border crossings. We provide composition statements in line with material data requests, and if a customer’s application relates to food or feed, additional documentation such as non-GMO declarations or allergen statements can be included.
For air and sea freight, we confirm DL‑Aspartic Acid does not require classification under IMDG (International Maritime Dangerous Goods) or IATA (International Air Transport Association) codes for dangerous substances. Our team regularly consults shipping partners about changing classification lists. Periodically, we update our logistics checklist and SDS formats following changes to GHS labeling standards or country-specific notification rules. Our packaging—sealed, food-grade drums or double-layered bags—prevents cross-contamination and damage, meeting both domestic and export quality criteria.
Customs bottlenecks arise if paperwork or product labeling fails to meet local interpretation of regulations, particularly for new destination markets. To prevent these, we train staff in the practicalities of country-of-origin labeling and compliance with product registration for countries where regulations change swiftly. Language- and content-specific documentation requests are handled directly by our compliance team, including translation to local languages when necessary.
Some jurisdictions request not just the usual SDS and CoA but additional customs commodity statements or written end-use declarations. We treat these as advance requirements, consulting regulatory bulletins and updating our export protocols. Since we require the most up-to-date regulatory developments, our regulatory affairs staff maintain direct lines of communication with industry bodies and shipping agencies to avoid disruption.
End-users and distributors rely on the manufacturer’s transparency and regulatory insight, especially when moving products across boundaries. By maintaining a direct, constantly updated regulatory pipeline, we ensure that our DL‑Aspartic Acid moves efficiently to any point on the globe. We monitor for classification or documentation changes affecting both large-scale and specialty chemical shipments and update our export files to match.
Our approach guarantees that every shipment of DL‑Aspartic Acid travels with the correct paperwork, meets prevailing import/export laws, and clears customs promptly, protecting our clients’ production timelines and supply chain reliability.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
